| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by first author.
Page 1: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1 | 4 | 28 | 1177 1995 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 28(10):1069-1076 AARESTRUP FM; GONCALVESDACOSTA SC; SARNO EN THE EFFECT OF THALIDOMIDE ON BCG-INDUCED GRANULOMAS IN MICE | 2 | 9 |
| 2 | 12 | 13 | 2524 2003 LEUKEMIA & LYMPHOMA 44(6):989-991 Abdalla SH; Mahmoud S Thalidomide in relapsed or refractory multiple myeloma: How much and for how long? | 1 | 1 |
| 3 | 0 | 0 | 2376 2003 BLOOD 102(11):453A-454A Abonour R; Ganjoo K; Fausel C; Yiannoutsos C; Juliar BE; Wood LL; Smith GG; Walker P; Cripe LD A phase II study of oral cyclophosphamide, thalidomide, and prednisone (CTP) for patients with relapsed or refractory multiple myeloma, a Hoosier Oncology Group (HOG) trial: HEM01-21. | 0 | 0 |
| 4 | 12 | 33 | 1697 2000 CLINICAL INFECTIOUS DISEASES 30(5):826-831 Aboulafia DM Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: Clinical improvement after initiation of thalidomide treatment | 1 | 4 |
| 5 | 1 | 6 | 1046 1991 JOURNAL OF LIQUID CHROMATOGRAPHY 14(4):667-673 ABOULENEIN HY; ISLAM MR DIRECT HPLC SEPARATION OF THALIDOMIDE ENANTIOMERS USING CELLULOSE TRIS-4-METHYLPHENYL BENZOATE CHIRAL STATIONARY PHASE | 9 | 17 |
| 6 | 4 | 22 | 2622 2004 EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 21(4):465-469 Abraham MH Hydrogen bond and other descriptors for thalidomide and its N-alkyl analogs; prediction of physicochemical and biological properties | 0 | 0 |
| 7 | 2 | 4 | 2220 2002 JOURNAL OF CLINICAL ONCOLOGY 20(4):1147-1149 Abramson N; Stokes PK; Luke M; Marks AR; Harris JM Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide | 0 | 3 |
| 8 | 1 | 3 | 1794 2000 TERATOLOGY 62(3):172-173 Adams J; Buttar HS; Chambers C; Collins TFX; Graham JM; Jones KL; Kweder S; Mitala J; Polifka JE; Schwetz BA; Public Affairs Comm Teratology society public affairs committee position paper: Thalidomide | 0 | 1 |
| 9 | 23 | 38 | 1622 2000 ANTI-CANCER DRUGS 11(10):787-791 Adlard JW Thalidomide in the treatment of cancer | 5 | 11 |
| 10 | 16 | 34 | 2214 2002 JOURNAL OF CARDIAC FAILURE 8(5):306-314 Agoston I; Dibbs ZI; Wang F; Muller G; Zeldis JB; Mann DL; Bozkurt B Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure | 2 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 11 | 0 | 0 | 755 1981 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 49(4):512-512 AGRAWAL KC; HASSAN KM; HASTINGS RC STRUCTURE ACTIVITY RELATIONSHIP STUDIES OF THALIDOMIDE ANALOGS AS ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE AGENTS | 0 | 0 |
| 12 | 0 | 0 | 2347 2003 BLOOD 102(11):237A-237A Agrawal NR; Hussein MA; Elson P; Karam MA; Reed J; Srkalovic G Pegylated Doxorubicin(D), Vineristine(V), reduced frequency Dexamethasone(D) and Thalidomide(T) (DVd-T) in newly diagnosed (Nmm) and relapsed/refractory (Rmm) multiple myeloma patients. | 0 | 0 |
| 13 | 0 | 0 | 2355 2003 BLOOD 102(11):378B-378B Agrawal NR; Srkalovic G; Sup S; Hsi ED; Elson P; Hussein MA Impact of pegylated doxorubicin(D), vincristine(V), reduced frequency dexamethasone(D) and thalidomide(T) {DVd-T} on bone marrow microvessel density (MVD) in newly diagnosed multiple myeloma (MM) patients (pts). | 0 | 0 |
| 14 | 0 | 0 | 1856 2001 BLOOD 98(11):307B-307B Ahmad I; Alam AR; Hahn T; Becker J; Chanan-Khan AA; Czuczman M; Bernstein S; Bernstein Z; McCarthy P Thalidomide plus VAD (vincristine, doxorabicin and dexamethasone) salvage therapy for VAD-refractory multiple myeloma, prior to autologous peripheral blood stem cell transplant (PBSCT). | 0 | 0 |
| 15 | 9 | 19 | 2130 2002 BONE MARROW TRANSPLANTATION 29(7):577-580 Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR Myeloma - Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT | 6 | 7 |
| 16 | 4 | 4 | 2493 2003 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 37(4):522-522 Ahmed M; El-Hadi S; Jenkins HR Thalidomide in Crohn disease and the risk of peripheral neuropathy | 0 | 0 |
| 17 | 0 | 1 | 2401 2003 BONE MARROW TRANSPLANTATION 31(11):1067-1067 Alam AR Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT - Reply to the letter by V Pitini | 0 | 0 |
| 18 | 0 | 0 | 2099 2002 BLOOD 100(11):390B-390B Alegre A; Gil-Fernandez JJ; Font P; Alonso A; Sureda A; Martinez-Chamorro C; Escudero A; Sanchez-Godoy P; Burgaleta C; Casado LF; Granda A; Aguado B; Osorio S; Nistal S; Mascunano R; Prieto E; Fernandez-Ranada JM Thalidomide as rescue of relapses after haematopoietic transplantation in multiple myeloma and as maintenance treatment: Results of a Spanish multicentre study including 63 patients. | 0 | 0 |
| 19 | 0 | 0 | 1855 2001 BLOOD 98(11):307B-307B Alegre A; Macias GR; Granda A; Golbano N; Martinez E; Alaez C; Blazquez C; Gongora E; Cannata J; Sanchez-Godoy P; Martinez-Chamorro C; Arranz R; de Soria VGG; Figuera A; Arranz E; Fernandez-Ranada JM Thalidomide as rescue treatment of relapses after haematopoietic transplantation in multiple myeloma. | 0 | 0 |
| 20 | 0 | 0 | 2596 2004 BONE MARROW TRANSPLANTATION 33:S356-S356 Alegre A; Martinez-Chamorro C; Escudero A; Aguado B; Osorio S; Nistal S; Cordoba R; Gil-Fernandez J; Sanchez-Godoy P; Burgaleta C; Casado F; Fernandez-Ranada JM Maintenance treatment with bisphosphonates plus interferon plus dexamethasone plus thalidomide (quadruple maintenance) after autologous peripheral blood stem cell transplantion in multiple myeloma: preliminary results | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 21 | 14 | 28 | 366 1966 BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE,USSR 61(2):185-& ALEKSAND.PN; BOGDANOV.VA; CHERNUKH AM TERATOGENIC EFFECT OF THALIDOMIDE IN EXPERIMENTS ON CHICK EMBRYOS | 0 | 0 |
| 22 | 2 | 6 | 381 1966 FEDERATION PROCEEDINGS 25(5P2S):T910-& ALEKSAND.PN; BOGDANOV.VA; CHERNUKH AM TERATOGENIC ACTION OF INTERMEDIATE PRODUCTS OF THALIDOMIDE SYNTHESIS ON CHICK EMBRYO | 0 | 1 |
| 23 | 8 | 16 | 1302 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(4):301-304 Alexander LN; Wilcox CM A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers | 25 | 32 |
| 24 | 5 | 42 | 1789 2000 SEMINARS IN HEMATOLOGY 37(1):35-39 Alexanian R; Anderson KC; Barlogie B; Stirling DI; Thomas DA Thalidomide in hematologic malignancies: Future directions | 5 | 5 |
| 25 | 0 | 10 | 1787 2000 SEMINARS IN HEMATOLOGY 37(1):22-25 Alexanian R; Weber D Thalidomide for resistant and relapsing myeloma | 22 | 26 |
| 26 | 12 | 17 | 2555 2003 SEMINARS IN HEMATOLOGY 40(4):3-7 Alexanian R; Weber D; Anagnostopoulos A; Delasalle K; Wang M; Rankin K Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma | 0 | 0 |
| 27 | 3 | 14 | 2031 2002 ANNALS OF ONCOLOGY 13(7):1116-1119 Alexanian R; Weber D; Giralt S; Delasalle K Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy | 6 | 9 |
| 28 | 0 | 0 | 1841 2001 BLOOD 98(11):163A-163A Alexanian R; Weber DM; Giralt S; Delasalle KB Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. | 0 | 2 |
| 29 | 9 | 12 | 2500 2003 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(5):S89-S91 Alfadley A; Al Rayes H; Hussein W; Al Dalaan A; Al-Aboud K Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus | 0 | 0 |
| 30 | 12 | 39 | 2467 2003 INTERNATIONAL JOURNAL OF DERMATOLOGY 42(5):372-375 Alfadley A; Al-Hawsawi K; Thestrup-Pedersen K; Al-Aboud K Treatment of prurigo nodularis with thalidomide: a case report and review of the literature | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 31 | 9 | 12 | 1884 2001 BRITISH JOURNAL OF DERMATOLOGY 144(2):227-228 Allen BR Thalidomide | 4 | 4 |
| 32 | 4 | 10 | 506 1970 JOURNAL OF THE CHEMICAL SOCIETY D-CHEMICAL COMMUNICATIONS (12):778-& ALLEN FH; TROTTER J CRYSTAL AND MOLECULAR STRUCTURE OF THALIDOMIDE | 1 | 0 |
| 33 | 4 | 37 | 525 1971 JOURNAL OF THE CHEMICAL SOCIETY B-PHYSICAL ORGANIC (6):1073-& ALLEN FH; TROTTER J CRYSTAL AND MOLECULAR STRUCTURE OF THALIDOMIDE, N-(ALPHA-GLUTARIMIDO)-PHTHALIMIDE | 5 | 29 |
| 34 | 0 | 0 | 582 1973 TEACHER OF THE DEAF 71(419):215-216 ALLEN G ARTIFICIAL EARS FOR A PROFOUNDLY DEAF THALIDOMIDE CHILD | 0 | 0 |
| 35 | 5 | 15 | 1692 2000 CHROMATOGRAPHIA 52(7-8):455-458 Alvarez C; Sanchez-Brunete JA; Torrado-Santiago S; Cadorniga R; Torrado JJ Enantioselective separation of thalidomide on on immobilized alpha(l)-acid glycoprotein chiral stationary phase | 0 | 2 |
| 36 | 0 | 0 | 2085 2002 BLOOD 100(11):375A-375A Alvi S; Borok RZ; Shaher A; Anthwal S; Shaikh M; Alvi I; Tahir S; John P; Shetty V; Galili N; Raza A Thalidomide significantly modifies bone marrow microenvironment in myelodysplastic syndrome (MDS) patients. | 0 | 0 |
| 37 | 0 | 0 | 1663 2000 BLOOD 96(11):356A-356A Alvi S; Henderson B; Shaher A; Dangerfield B; Broderick E; Jafri N; Tareen M; Du Randt M; Galili N; Borok RZ; Raza A Determination of clonality in stromal and parenchymal cells pre and post thalidomide treatment in myelodysplasia. | 0 | 0 |
| 38 | 0 | 0 | 1664 2000 BLOOD 96(11):359A-359A Alvi S; Shaher A; Henderson B; Dar S; Zorat F; Broderick E; Lisak L; Du Randt M; Reddy P; Mundle S; Galili N; Borok RZ; Raza A Improved growth of stromal cells in long term bone marrow cultures (LTBMC) of myelodysplastic syndrome (MDS) patients treated with thalidomide. | 0 | 1 |
| 39 | 0 | 0 | 1864 2001 BLOOD 98(11):351A-352A Alvi S; Shaher A; Shaikh M; Anthwal S; Siddiqi F; Akhtar A; Ashraf H; Meagher R; Mundle S; Shetty V; Goldberg C; Galili N; Borok RZ; Raza A MDS patients with hematological response to thalidomide show enhanced in vitro growth potential. | 0 | 0 |
| 40 | 0 | 0 | 1865 2001 BLOOD 98(11):352A-352A Alvi S; Shaikh M; Anthwal S; Shaher A; Tamoseviciene D; Novick A; Reddy P; Allampallam K; Hsu WT; Galili N; Borok RZ; Raza A Cytogenetic and clonal profile of myelodysplastic syndromes (MDS) patients treated with thalidomide. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 41 | 7 | 18 | 1778 2000 ONCOLOGY-NEW YORK 14(12):33-36 Amato R Thalidomide for recurrent renal-cell cancer in a 40-year-old man | 2 | 2 |
| 42 | 13 | 38 | 2444 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S59-S65 Amato RJ Thalidomide therapy for renal cell carcinoma | 0 | 1 |
| 43 | 2 | 15 | 503 1970 EXPERIENTIA 26(7):796-& AMIRKHAN.JD THALIDOMIDE AS A MUTAGENIC AGENT IN MOSQUITO (CULEX-PIPIENS MOLESTUS) | 0 | 1 |
| 44 | 0 | 0 | 2378 2003 BLOOD 102(11):454A-454A Anagnostopoulos A; Efstathiou E; Hamilos G; Zorzou MP; Kastritis E; Dimopoulos MA Patterns of progression in myeloma patients treated with thalidomide-based regimens: High incidence of extramedullary progression without serologic relapse. | 0 | 0 |
| 45 | 0 | 0 | 1416 1998 BONE MARROW TRANSPLANTATION 21:S113-S113 Anagnostopoulos A; Fassas A; Giannaki E; Sakellari I; Tzarou V; Smias C; Lalayanni C; Papaioannou G; Gakos E Treatment of resistant chronic GVHD with thalidomide. | 0 | 0 |
| 46 | 10 | 18 | 2658 2004 LEUKEMIA & LYMPHOMA 45(1):113-116 Anagnostopoulos A; Hamilos G; Zorzou MP; Grigoraki V; Anagnostou D; Dimopoulos MA Discordant response or progression in patients with myeloma treated with thalidomide-based regimens | 0 | 0 |
| 47 | 4 | 12 | 2415 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(5):768-771 Anagnostopoulos A; Weber D; Rankin K; Delasalle K; Alexanian R Thalidomide and dexamethasone for resistant multiple myeloma | 11 | 16 |
| 48 | 0 | 0 | 2395 2003 BLOOD 102(11):938A-938A Anagnostopoulos A; Zervas K; Zomas A; Pouli A; Hamilos G; Anagnostopoulos N; Dimopoulos MA The International Prognostic Index (IPI) is predictive for survival in refractory or relapsed myeloma patients treated with thalidomide-based regimens. | 0 | 0 |
| 49 | 0 | 0 | 2377 2003 BLOOD 102(11):454A-454A Anaissie EJ; Jacobson J; Fassas AB; Zangari M; Thertulien R; VanRhee F; Talamo G; Tricot G; Wendling C; Davis CK; Hollmig K; Barlogie B Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients. | 0 | 0 |
| 50 | 4 | 11 | 2271 2002 OBSTETRICS AND GYNECOLOGY 99(1):125-128 Ances BM New concerns about thalidomide | 1 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 51 | 0 | 0 | 1833 2001 BLOOD 98(11):52B-52B Anders O; Plath F; Emmrich J; Freund M Complete remission of therapy-resistant angiodysplasia of the stomach in myelodysplastic syndrome following thalidomide. | 0 | 0 |
| 52 | 9 | 27 | 1784 2000 SEMINARS IN HEMATOLOGY 37(1):1-4 Anderson KC Thalidomide: Therapeutic potential in hematologic malignancies | 6 | 8 |
| 53 | 3 | 8 | 673 1978 JAPANESE HEART JOURNAL 19(5):823-827 ANDO J; KOBAYASHI T; SATO R; YASUDA H CONGENITAL AORTIC REGURGITATION OBSERVED IN A THALIDOMIDE-DEFORMED CHILD | 0 | 1 |
| 54 | 17 | 29 | 2149 2002 CANCER BIOLOGY & THERAPY 1(6):669-673 Ando L; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide | 0 | 0 |
| 55 | 28 | 54 | 2161 2002 CLINICAL CANCER RESEARCH 8(6):1964-1973 Ando Y; Fuse E; Figg WD Thalidomide metabolism by the CYP2C subfamily | 13 | 14 |
| 56 | 0 | 0 | 2283 2002 PHARMACOTHERAPY 22(10):1362-1362 Ando Y; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetics of thalidomide: drug response, in vivo metabolism and genetic polymorphism of CYP2C19. | 0 | 0 |
| 57 | 1 | 6 | 2525 2003 LEUKEMIA & LYMPHOMA 44(6):1081-1082 Andretta C; Catalano L; Pace L; Fonti R; Annunziata G; Rotoli B 99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients | 0 | 1 |
| 58 | 8 | 24 | 1484 1999 AMERICAN JOURNAL OF PUBLIC HEALTH 89(1):98-101 Annas GJ; Elias S Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century | 5 | 7 |
| 59 | 15 | 16 | 2677 2004 NEUROLOGY 62(12):2158-2159 Apfel SC; Zochodne DW Thalidomide neuropathy - Too much or too long? | 0 | 0 |
| 60 | 0 | 3 | 340 1965 JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 192(2):173-& APGAR V SEARCH FOR BIRTH DATA ON THALIDOMIDE-SENSITIVE PERIOD | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 61 | 0 | 0 | 68 1962 BRITISH MEDICAL JOURNAL (5303):545-& APPLEBEY M HELP FOR THALIDOMIDE BABIES | 0 | 0 |
| 62 | 22 | 45 | 1162 1994 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 40(5):535-542 ARALACHAVES M; VILANOVA M; RIBEIRO A; PINTO J IMMUNOSTIMULATORY EFFECT OF THALIDOMIDE IN NORMAL C57BL/6 MICE IS COMPATIBLE WITH STIMULATION OF A HIGHLY CONNECTED CENTRAL IMMUNE-SYSTEM .1. | 4 | 6 |
| 63 | 5 | 6 | 672 1978 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 239(16):1608-1609 ARCHER J THALIDOMIDE AND NEUROLOGICAL DAMAGE REVISITED | 0 | 0 |
| 64 | 13 | 66 | 1463 1998 MEDICAL HYPOTHESES 50(4):313-318 Argiles JM; Carbo N; Lopez-Soriano FJ Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? | 11 | 12 |
| 65 | 0 | 0 | 868 1984 TERATOLOGY 30(1):A36-A36 ARIMOTO H OCULAR FINDINGS OF THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 66 | 0 | 0 | 1834 2001 BLOOD 98(11):52B-52B Arkel YS; Ku DHW; Le P Effect of thalidomide on tissue factor activity in monocytic and endothelial cell lines, and relationship to tumor necrosis factor-alpha (TNF). | 0 | 0 |
| 67 | 8 | 12 | 2506 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(12):2691-2692 Arkel YS; Ku DHW; Thurston AL The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)- alpha-stimulated cells | 0 | 0 |
| 68 | 23 | 76 | 1280 1996 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 277(3):1649-1658 Arlen RR; Wells PG Inhibition of thalidomide teratogenicity by acetylsalicylic acid: Evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate | 9 | 15 |
| 69 | 0 | 0 | 208 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 88(19):980-& ARMSTRONG KS HABILITATION OF PATIENTS WITH CONGENITAL MALFORMATIONS ASSOCIATED WITH THALIDOMIDE - MEDICAL-SOCIAL ASPECTS | 1 | 1 |
| 70 | 5 | 10 | 924 1986 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 14(2):282-283 ARONSON IK; WEBER L; WEST D; BUYS C; REDER A; ANTEL J THALIDOMIDE AND LYMPHOCYTE FUNCTION | 6 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 71 | 17 | 35 | 843 1984 ARCHIVES OF DERMATOLOGY 120(11):1466-1470 ARONSON IK; YU R; WEST DP; VANDENBROEK H; ANTEL J THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - EFFECT OF SERUM FACTOR ON NERVE CULTURES | 34 | 38 |
| 72 | 0 | 0 | 848 1984 CLINICAL RESEARCH 32(2):A569-A569 ARONSON IK; YU R; WEST DP; VANDENBROEK H; ANTEL J THALIDOMIDE INDUCED PERIPHERAL NEUROPATHY - EFFECT OF SERUM FACTOR ON NERVE CULTURES | 0 | 0 |
| 73 | 4 | 18 | 1824 2001 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 7(5):265-273 Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WF; Weisdorf DJ Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease | 8 | 15 |
| 74 | 28 | 44 | 2208 2002 INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 83(2):99-104 Arrieta O; Guevara P; Tamariz J; Rembao D; Rivera E; Sotelo J Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma | 1 | 3 |
| 75 | 4 | 24 | 1553 1999 INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 80(1):11-16 Arrieta O; Ortiz-Reyes A; Rembao D; Calvillo M; Rivera E; Sotelo J Protective effect of pentoxifylline plus thalidomide against septic shock in mice | 4 | 8 |
| 76 | 3 | 38 | 2597 2004 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 37(4):485-492 Arruda MSP; Richini VB; Oliveira SMA; Vilani-Moreno FR Experimental murine mycobacteriosis: evaluation of the functional activity of alveolar macrophages in thalidomide-treated mice | 0 | 0 |
| 77 | 3 | 15 | 930 1986 REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO 28(1):12-14 ARRUDA WO; HACBARTH E; DOI E; SANTAMARIA JR; BARBOSA J; KAJDACSYBALLA AA EFFECT OF THALIDOMIDE ON SERUM LEVELS OF IMMUNOGLOBULINS IGM AND IGA, RHEUMATOID-FACTOR AND ISOHEMAGLUTININS ANTI-A AND ANTI-B IN PATIENTS WITH LEPROMATOUS LEPROSY - A DOUBLE-BLIND-STUDY | 1 | 2 |
| 78 | 0 | 0 | 714 1979 TERATOLOGY 20(1):176-177 ASAKA A; KIDA M THALIDOMIDE EMBRYOPATHY IN TWINS | 0 | 0 |
| 79 | 0 | 0 | 659 1977 TERATOLOGY 16(1):102-102 ASAKA A; SAITO T; NAGASAWA M; KANNO T; KIDA M NEUROPSYCHIATRIC INVOLVEMENT IN PATIENTS WITH THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 80 | 6 | 35 | 1341 1997 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 19(3):313-326 Aseffa A; Dietrich MA; Shannon EJ Effect of thalidomide on apoptosis of lymphocytes and neutrophils | 4 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 81 | 2 | 5 | 1373 1997 NATURE 389(6647):118-118 Ashby J Thalidomide is not a mutagen | 3 | 4 |
| 82 | 4 | 11 | 1216 1995 NATURE 375(6531):453-453 ASHBY J; TINWELL H IS THALIDOMIDE MUTAGENIC | 7 | 11 |
| 83 | 5 | 5 | 2146 2002 BRITISH MEDICAL JOURNAL 325(7374):1245-1245 Ashby J; Tinwell H Thalidomide is not a human mutagen | 0 | 0 |
| 84 | 16 | 59 | 1371 1997 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 396(1-2):45-64 Ashby J; Tinwell H; Callander RD; Kimber I; Clay P; Galloway SM; Hill RB; Greenwood SK; Gaulden ME; Ferguson MJ; Vogel E; Nivard M; Parry JM; Williamson J Thalidomide: lack of mutagenic activity across phyla and genetic endpoints | 12 | 14 |
| 85 | 1 | 3 | 1130 1994 BRITISH MEDICAL JOURNAL 309(6948):193-194 ASSCHER W SAFETY OF THALIDOMIDE | 2 | 2 |
| 86 | 0 | 1 | 287 1964 JOURNAL OF TEACHER EDUCATION 15(4):382-385 ATKYNS GC A THALIDOMIDE SCANDAL IN EDUCATION | 0 | 1 |
| 87 | 21 | 33 | 1095 1993 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 11(5):487-493 ATRA E; SATO EI TREATMENT OF THE CUTANEOUS LESIONS OF SYSTEMIC LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 46 | 64 |
| 88 | 3 | 30 | 1154 1994 MIKROCHIMICA ACTA 117(1-2):75-85 AUCELIO RQ; CAMPIGLIA AD PHARMACEUTICAL FORMULATION ANALYSIS OF THALIDOMIDE BY SOLID-SURFACE ROOM-TEMPERATURE PHOSPHORIMETRY | 1 | 10 |
| 89 | 18 | 32 | 1121 1994 BIOGENIC AMINES 10(6):543-554 AUDIT CO THALIDOMIDE-INDUCED POLYAMINE ACYLATION - A NEW INSIGHT INTO THE ACYLATION MECHANISM | 3 | 3 |
| 90 | 8 | 65 | 1246 1996 BIOGENIC AMINES 12(4):305-326 Audit CO Specific functions of polyamines: Actin assembly, cytokinesis induction, targets for thalidomide activity, nitrogen sources for marine ecosystems | 1 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 91 | 6 | 6 | 1369 1997 M S-MEDECINE SCIENCES 13(4):595-596 Audit CO; Aimar C Thalidomide-induced teratogenesis. | 0 | 0 |
| 92 | 23 | 39 | 1258 1996 DEVELOPMENT GROWTH & DIFFERENTIATION 38(1):47-57 Audit CO; Eger K; Aimar C Possible involvement of an acylation mechanism in thalidomide-induced teratogenesis of the newt (Pleurodeles waltl) | 2 | 2 |
| 93 | 3 | 18 | 2155 2002 CHEMICAL COMMUNICATIONS (19):2242-2243 Augusti DV; Augusti R; Carazza F; Cooks RG Quantitative determination of the enantiomeric composition of thalidomide solutions by electrospray ionization tandem mass spectrometry | 0 | 0 |
| 94 | 0 | 1 | 1366 1997 LANCET 350(9081):873-873 Ault A Thalidomide comes close to US approval | 1 | 1 |
| 95 | 0 | 0 | 1460 1998 LANCET 352(9124):298-298 Ault A Thalidomide makes a return to US health care | 0 | 0 |
| 96 | 10 | 60 | 2569 2004 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 19(1):79-88 Austin AS; Mahida YR; Clarke D; Ryder SD; Freeman JG A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis | 0 | 0 |
| 97 | 0 | 0 | 1933 2001 GUT 48:A67-A68 Austin AS; Mahida YR; Ryder SD; Freeman JG Thalidomide but not pentoxifylline lowers portal pressure in human alcoholic cirrhosis | 0 | 0 |
| 98 | 0 | 0 | 1963 2001 JOURNAL OF HEPATOLOGY 34:18-18 Austin AS; Mahida YR; Ryder SD; Freeman JG Thalidomide but not pentoxifylline lowers portal pressure in human alcoholic cirrhosis | 0 | 0 |
| 99 | 0 | 0 | 1861 2001 BLOOD 98(11):311B-311B Avalos JS; Barazzutti L; Korin J; Kusminsky G; Ferro H; Tavella O; Foncuberta M; Tartas N Thalidomide and cranial nerves neuropathies. | 0 | 0 |
| 100 | 7 | 18 | 875 1985 ARCHIVOS DE INVESTIGACION MEDICA 16(2):139-143 AVALOSDIAZ E; GUZMANENRIQUEZ L; LOPEZROBLES E; HERRERAESPARZA R INHIBITORY EFFECT OF ENDOCYTOSIS IN POLIMORPHONUCLEAR CELLS CAUSED BY THALIDOMIDE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 101 | 8 | 17 | 1976 2001 LEUKEMIA & LYMPHOMA 42(4):683-+ Avigdor A; Raanani P; Levi I; Hardan I; Ben-Bassat I Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma | 8 | 9 |
| 102 | 13 | 18 | 1961 2001 JOURNAL OF CLINICAL PHARMACOLOGY 41(10):1091-1097 Aweeka F; Trapnell C; Chernoff M; Jayewardene A; Spritzler J; Bellibas SE; Lizak P; Jacobson J Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251 | 6 | 7 |
| 103 | 0 | 0 | 1078 1992 TROPICAL DOCTOR 22(3):139-139 AWOFESO N THALIDOMIDE PERIPHERAL NEUROPATHY | 1 | 4 |
| 104 | 1 | 3 | 846 1984 BRITISH JOURNAL OF DERMATOLOGY 111(1):125-126 AYRES S THALIDOMIDE OR VITAMIN-E THERAPY FOR DISCOID LUPUS-ERYTHEMATOSUS | 1 | 2 |
| 105 | 1 | 4 | 887 1985 INTERNATIONAL JOURNAL OF DERMATOLOGY 24(9):616-616 AYRES S DISCOID LUPUS-ERYTHEMATOSUS - THALIDOMIDE OR VITAMIN-E | 0 | 1 |
| 106 | 0 | 10 | 12 1961 AMERICAN JOURNAL OF PSYCHIATRY 118(6):554-& AZIMA H; ARTHURS D CONTROL STUDY OF THALIDOMIDE (KEVADON), A NEW HYPNOTIC AGENT | 0 | 2 |
| 107 | 0 | 0 | 2437 2003 CLINICAL CANCER RESEARCH 9(16):6150S-6150S Baas P; Haringhuizen A; Boogerd W; Dalesio O; Van Zandwijk N Thalidomide in malignant pleural mesothelioma: Results of a phase II study. | 0 | 0 |
| 108 | 24 | 55 | 1993 2001 OPHTHALMIC RESEARCH 33(5):256-263 Baatz H; Tonessen B; Prada J; Pleyer U Thalidomide inhibits leukocyte-endothelium interaction in endotoxin-induced uveitis | 1 | 4 |
| 109 | 0 | 0 | 1349 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):5409-5409 Baatz H; Tonnessen B; Pleyer U; Hartmann C Thalidomide inhibits leukocyte-endothelium-interaction in endotoxin-induced uveitis | 0 | 0 |
| 110 | 0 | 0 | 1456 1998 JOURNAL OF VASCULAR RESEARCH 35:54-54 Baatz H; Tonnessen B; Pleyer U; Hartmann C Antiinflammatory action of thalidomide: Modulation of leukocyte-endothelium interaction | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 111 | 23 | 44 | 183 1963 ACTA PATHOLOGICA ET MICROBIOLOGICA SCANDINAVICA 59(4):491-& BACH A; BICHEL J; HEJGAARD JJ STUDIES ON POSSIBLE ANTI-NEOPLASTIC EFFECT OF THALIDOMIDE | 4 | 9 |
| 112 | 5 | 23 | 2258 2002 LEUKEMIA & LYMPHOMA 43(6):1267-1271 Badros A; Morris C; Zangari M; Barlogie B; Tricot G Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia | 3 | 3 |
| 113 | 0 | 0 | 1647 2000 BLOOD 96(11):285B-285B Badros A; Zangari M; Bodenner D; Siegel E; Spoon D; Toor A; Desikan R; Arnold E; Anaissie E; Zeldis J; Tricot G; Barlogie B Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide. | 0 | 3 |
| 114 | 0 | 0 | 2384 2003 BLOOD 102(11):684A-684A Badros AZ; Ratterree B; Natt S; Rapoport AP; Zeldis JB; Frankel SR; Meisenberg B; Takebe N; Zwiebel JA; Zhang B; Fenton R Phase I/II trial of oblimersen sodium (G3139), dexamethasone (Dex) and thalidomide (Thal) in patients with relapsed multiple myeloma. | 0 | 0 |
| 115 | 6 | 16 | 2025 2002 AMERICAN JOURNAL OF MEDICINE 112(5):412-413 Badros AZ; Siegel E; Bodenner D; Zangari M; Zeldis J; Barlogie B; Tricot G Hypothyroidism in patients with multiple myeloma following treatment with thalidomide | 8 | 9 |
| 116 | 0 | 0 | 2104 2002 BLOOD 100(11):393A-393A Bahlis NJ; Sawney R; Gerson S PKC delta inhibition induces cell death in thalidomide and dexamethasone resistant multiple myeloma cell lines. | 0 | 0 |
| 117 | 4 | 7 | 772 1982 ACTA DERMATO-VENEREOLOGICA 62(5):449-450 BAHMER FA; ZAUN H; LUSZPINSKI P THALIDOMIDE TREATMENT OF RECURRENT ERYTHEMA MULTIFORME | 19 | 25 |
| 118 | 94 | 118 | 2151 2002 CANCER INVESTIGATION 20(5-6):835-848 Baidas S; Tfayli A; Bhargava P Thalidomide: An old drug with new clinical applications | 1 | 3 |
| 119 | 27 | 40 | 1741 2000 JOURNAL OF CLINICAL ONCOLOGY 18(14):2710-2717 Baidas SM; Winer EP; Fleming GF; Harris L; Pluda JM; Crawford JG; Yamauchi H; Isaacs C; Hanfelt J; Tefft M; Flockhart D; Johnson MD; Hawkins MJ; Lippman ME; Hayes DF Phase II evaluation of thalidomide in patients with metastatic breast cancer | 38 | 53 |
| 120 | 4 | 13 | 2659 2004 LEUKEMIA & LYMPHOMA 45(1):179-181 Baird R; van Zyl-Smit RN; Iveson A; Duddy J; Rassam S Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 121 | 6 | 27 | 468 1968 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 161(2):348-& BAKAY B; NYHAN WL BINDING THALIDOMIDE BY MACROMOLECULES IN FETAL AND MATERNAL RAT | 11 | 16 |
| 122 | 1 | 14 | 504 1970 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 171(1):109-& BAKAY B; NYHAN WL EFFECTS OF THALIDOMIDE AND CHLORCYCLIZINE ON BIOSYNTHESIS OF NUCLEIC ACIDS AND PROTEINS IN FETAL AND MATERNAL TISSUES OF RAT | 4 | 5 |
| 123 | 0 | 0 | 1866 2001 BLOOD 98(11):353A-354A Baker AF; Bellamy WT; Glinsmann-Gibson BJ; Heaton R; Buresh A; Grogan TM; List AF Biological response to thalidomide in remitting patients with myelodysplastic syndrome (MDS): Evidence for induction of neoplastic vascular endothelial growth factor (VEGF) resistance. | 0 | 0 |
| 124 | 0 | 1 | 695 1979 COLUMBIA JOURNALISM REVIEW 18(2):74-74 BALK A SUFFER THE CHILDREN - STORY OF THALIDOMIDE | 0 | 0 |
| 125 | 10 | 11 | 1306 1997 AMERICAN JOURNAL OF GASTROENTEROLOGY 92(1):169-170 Ball SC; Sepkowitz KA; Jacobs JL Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: Case report and review | 12 | 13 |
| 126 | 14 | 20 | 2660 2004 LEUKEMIA & LYMPHOMA 45(4):735-738 Balleari E; Ghio R; Falcone A; Musto P Possible multiple myeloma dedifferentiation following thalidomide therapy: A report of four cases | 0 | 0 |
| 127 | 0 | 0 | 2342 2003 BLOOD 102(11):56B-56B Ballester G; Ballester O; Daitch L; Kutlar A Response to thalidomide therapy in multicentric Castleman's disease. | 0 | 0 |
| 128 | 6 | 10 | 2504 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):421-422 Barbui T; Falanga A Thalidomide and thrombosis in multiple myeloma | 1 | 1 |
| 129 | 14 | 25 | 2228 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(2):135-139 Bariol C; Meagher AP; Vickers CR; Byrnes DJ; Edwards PD; Hing M; Wettstein AR; Field A Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease | 8 | 13 |
| 130 | 1 | 4 | 1768 2000 NEW ENGLAND JOURNAL OF MEDICINE 342(13):975-976 Barlogie B Thalidomide in multiple myeloma - Reply | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 131 | 7 | 20 | 2554 2003 SEMINARS IN HEMATOLOGY 40(4):1-2 Barlogie B Introduction: Thalidomide and the IMiDs in multiple myeloma | 0 | 0 |
| 132 | 11 | 14 | 2558 2003 SEMINARS IN HEMATOLOGY 40(4):33-38 Barlogie B Thalidomide and CC-5013 in multiple myeloma: The University of Arkansas experience | 0 | 0 |
| 133 | 9 | 21 | 1830 2001 BLOOD 98(2):492-494 Barlogie B; Desikan R; Eddlemon P; Spencer T; Zeldis J; Munshi N; Badros A; Zangari M; Anaissie E; Epstein J; Shaughnessy J; Ayers D; Spoon D; Tricot G Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients | 66 | 111 |
| 134 | 0 | 0 | 1670 2000 BLOOD 96(11):514A-514A Barlogie B; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 14 |
| 135 | 8 | 18 | 2006 2001 SEMINARS IN ONCOLOGY 28(6):577-582 Barlogie B; Tricot G; Anaissie E Thalidomide in the management of multiple myeloma | 10 | 17 |
| 136 | 0 | 0 | 2073 2002 BLOOD 100(11):210A-210A Barlogie B; Tricot G; Anaissie E; Fassas A; Lee CK; Thertulien R; van Rhee F; Zangari M Long-term follow-up (median of 4 yr) of 169 patients receiving thalidomide (THAL) for advanced and refractory multiple myeloma (MM): Superior survival in the absence of cytogenetic abnormalities (CA) and low beta-2 microglobulin (B2M). | 0 | 0 |
| 137 | 6 | 48 | 2004 2001 SEMINARS IN HEMATOLOGY 38(3):250-259 Barlogie B; Zangari M; Spencer T; Fassas A; Anaissie E; Badros A; Cromer J; Tricot G Thalidomide in the management of multiple myeloma | 18 | 31 |
| 138 | 0 | 0 | 1974 2001 LEUKEMIA 15(3):491-491 Barlogie D; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 0 |
| 139 | 0 | 0 | 1284 1996 LANCET 348(9038):1370-1370 Barnett AA FDA encourages firms to test thalidomide | 0 | 0 |
| 140 | 0 | 0 | 1365 1997 LANCET 349(9045):111-111 Barnett AA Company applies to market thalidomide in USA | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 141 | 2 | 3 | 894 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(2):305-305 BARNHILL RL THALIDOMIDE AND OXYGEN INTERMEDIATES - REPLY | 0 | 0 |
| 142 | 22 | 39 | 855 1984 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 11(5):814-819 BARNHILL RL; DOLL NJ; MILLIKAN LE; HASTINGS RC STUDIES ON THE ANTI-INFLAMMATORY PROPERTIES OF THALIDOMIDE - EFFECTS ON POLYMORPHONUCLEAR LEUKOCYTES AND MONOCYTES | 42 | 48 |
| 143 | 26 | 54 | 784 1982 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 7(3):317-323 BARNHILL RL; MCDOUGALL AC THALIDOMIDE - USE AND POSSIBLE MODE OF ACTION IN REACTIONAL LEPROMATOUS LEPROSY AND IN VARIOUS OTHER CONDITIONS | 84 | 111 |
| 144 | 5 | 45 | 456 1968 BULLETIN DU CANCER 55(3):413-& BAROCHE C ACTIONS OF THALIDOMIDE ON DROSOPHILA WITH REGARD TO DEVELOPMENT AND TUMORIGENESIS - COMPARISONS WITH EFFECT OF POTASSIUM PHTHALATE AND SOME NON-PHTHALATE COMPOUNDS | 1 | 1 |
| 145 | 0 | 0 | 2119 2002 BLOOD 100(11):800A-800A Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A Thalidomide in Myelofibrosis with Myeloid Metaplasia: A pooled-analysis of individual patient data from five studies. | 0 | 0 |
| 146 | 0 | 0 | 1675 2000 BLOOD 96(11):746A-746A Barosi G; Grossi A; Comotti B; Marchetti M Thalidomide in patients with myelofibrosis with myeloid metaplasia. | 0 | 4 |
| 147 | 12 | 22 | 1888 2001 BRITISH JOURNAL OF HAEMATOLOGY 114(1):78-83 Barosi G; Grossi A; Comotti B; Musto P; Gamba G; Marchetti M Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia | 12 | 23 |
| 148 | 1 | 2 | 830 1983 PRESSE MEDICALE 12(15):963-963 BARRIERE H SARCOIDOSIS OF THE SKIN - TREATMENT WITH THALIDOMIDE | 12 | 16 |
| 149 | 4 | 12 | 484 1969 FOLIA PRIMATOLOGICA 10(3):195-& BARROW MV; STEFFEK AJ; KING CTG THALIDOMIDE SYNDROME IN RHESUS MONKEYS (MACACA MULATTA) | 4 | 9 |
| 150 | 0 | 0 | 1815 2001 ARTHRITIS AND RHEUMATISM 44(9):S125-S125 Barthel HR Successful treatment of Weber Christian disease (WCD) with thalidomide in a patient failing multiple other medical therapies | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 151 | 5 | 40 | 2213 2002 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 8(5):256-259 Barthel HR; Charrier U; Kramer M; Loch C Successful treatment of idiopathic febrile panniculitis (Weber-Christian disease) with thalidomide in a patient having failed multiple other medical therapies | 0 | 0 |
| 152 | 0 | 1 | 38 1961 BRITISH MEDICAL JOURNAL 2(526):1570-& BARTHOLOMAY A NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 0 | 9 |
| 153 | 44 | 57 | 2676 2004 NATURE REVIEWS CANCER 4(4):314-322 Bartlett JB; Dredge K; Dalgleish AG Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents | 1 | 1 |
| 154 | 32 | 40 | 2598 2004 BRITISH JOURNAL OF CANCER 90(5):955-961 Bartlett JB; Michael A; Clarke IA; Dredge K; Nicholson S; Kristeleit H; Polychronis A; Pandha H; Muller GW; Stirling DI; Zeldis J; Dalgleish AG Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers | 1 | 1 |
| 155 | 3 | 10 | 2302 2003 AMERICAN JOURNAL OF HEMATOLOGY 74(3):205-207 Barton JC Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia | 0 | 0 |
| 156 | 0 | 6 | 71 1962 BRITISH MEDICAL JOURNAL (5305):672-& BASSIL GT; RIESS W; SCHMID K; KEBERLE H; FAIGLE JW THALIDOMIDE AND GLUTETHIMIDE | 0 | 0 |
| 157 | 20 | 24 | 2235 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):1020-1026 Bastuji-Garin S; Ochonisky S; Bouche P; Gherardi RK; Duguet C; Djerradine Z; Poli F; Revuz J; Thalidomide Neuropathy Study Grp Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients | 9 | 12 |
| 158 | 0 | 0 | 513 1971 ANATOMICAL RECORD 169(2):274-& BATTINIC.WR EFFECTS OF THALIDOMIDE ON EARLY LIMB DEVELOPMENT IN RHESUS MONKEY (MACACA-MULATTA) | 0 | 1 |
| 159 | 6 | 21 | 2626 2004 GUT 53(4):609-612 Bauditz J; Schachschal G; Wedel S; Lochs H Thalidomide for treatment of severe intestinal bleeding | 0 | 0 |
| 160 | 0 | 0 | 2189 2002 GASTROENTEROLOGY 122(4):A194-A194 Bauditz J; Wedel S; Lochs H Thalidomide for treatment of intestinal bleeding: Correlation to VEGF | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 161 | 13 | 36 | 2194 2002 GUT 50(2):196-200 Bauditz J; Wedel S; Lochs H Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease | 11 | 25 |
| 162 | 0 | 0 | 1715 2000 GASTROENTEROLOGY 118(4):A580-A580 Bauditz L; Wedel S; Suk A; Lochs H Cytokine profiles under treatment with Thalidomide steroid-resistant Crohn's disease. | 0 | 0 |
| 163 | 4 | 5 | 2137 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(4):996-997 Bauduer F Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma | 0 | 0 |
| 164 | 9 | 42 | 2487 2003 JOURNAL OF INTERFERON AND CYTOKINE RESEARCH 23(1):3-10 Bauer JA; Morrison BH; Grane RW; Jacobs BS; Borden EC; Lindner DJ IFN-alpha 2b and thalidomide synergistically inhibit tumor-induced angiogenesis | 0 | 2 |
| 165 | 13 | 27 | 1406 1998 BIOCHEMICAL PHARMACOLOGY 55(11):1827-1834 Bauer KS; Dixon SC; Figg WD Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent | 80 | 120 |
| 166 | 15 | 29 | 2156 2002 CHEST 122(1):227-232 Baughman RP; Judson MA; Teirstein AS; Moller DR; Lower EE Thalidomide for chronic sarcoidosis | 4 | 24 |
| 167 | 0 | 1 | 1093 1993 CHEMICAL & ENGINEERING NEWS 71(28):5-5 BAUM R THALIDOMIDE BLOCKS VIRUS THAT CAUSES AIDS | 0 | 0 |
| 168 | 8 | 30 | 2645 2004 JOURNAL OF NEURO-ONCOLOGY 67(1-2):191-200 Baumann F; Bjeljac M; Kollias SS; Baumert BG; Brandner S; Rousson V; Yonekawa Y; Bernays RL Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme | 0 | 0 |
| 169 | 7 | 24 | 648 1977 JOURNAL OF EMBRYOLOGY AND EXPERIMENTAL MORPHOLOGY 41(OCT):125-135 BAZZOLI AS; MANSON J; SCOTT WJ; WILSON JG EFFECTS OF THALIDOMIDE AND 2 ANALOGS ON REGENERATING FORELIMB OF NEWT | 4 | 17 |
| 170 | 0 | 0 | 657 1977 TERATOLOGY 15(2):A24-A25 BAZZOLI AS; SCOTT WJ; MANSON J; WILSON JG THALIDOMIDE INDUCED LIMB MALFORMATIONS IN REGENERATING NEWT FORELIMB | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 171 | 0 | 6 | 833 1983 TERATOLOGY 27(2):A29-A30 BECK SL PAUCITY OF POSTNATAL EFFECTS ON CD-1 MOUSE SKELETON OF PRENATAL EXPOSURE TO CAPTAN, THALIDOMIDE, CORTISONE, OR DIPHENYLHYDANTOIN | 0 | 3 |
| 172 | 0 | 189 1963 ARZNEIMITTEL-FORSCHUNG 13:185-191 BECKMANN R The behavior of thalidomide in the human and animal organism. part 2. | 35 | 47 | |
| 173 | 12 | 44 | 1743 2000 JOURNAL OF INFECTIOUS DISEASES 181(3):954-965 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis | 18 | 27 |
| 174 | 1 | 1 | 1744 2000 JOURNAL OF INFECTIOUS DISEASES 181(4):1521-1521 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. (vol 181, pg 954, 2000) | 0 | 0 |
| 175 | 0 | 0 | 1012 1990 GAZETTE MEDICALE 97(3):26-27 BELAICH S USE OF THALIDOMIDE IN DERMATOLOGY | 0 | 0 |
| 176 | 21 | 38 | 832 1983 SEMAINE DES HOPITAUX 59(45):3101-3104 BELAUBE P; GARCIN G; MARCHAND JP; PRIVAT Y SHOULD THALIDOMIDE BE REHABILITATED | 4 | 7 |
| 177 | 0 | 0 | 455 1968 BRITISH MEDICAL JOURNAL 4(5624):190-& BELL R THALIDOMIDE | 0 | 0 |
| 178 | 0 | 2 | 517 1971 BRITISH MEDICAL JOURNAL 3(5767):186-& BELL R THALIDOMIDE | 0 | 0 |
| 179 | 9 | 14 | 1263 1996 GASTROINTESTINAL ENDOSCOPY 44(6):729-731 Bellomo A; SchorrLesnick B Thalidomide treatment for idiopathic esophageal ulcers in patients with HIV | 0 | 1 |
| 180 | 22 | 36 | 1948 2001 INFLAMMATION 25(2):91-96 Belo AV; Ferreira MAND; Bosco AA; Machado RDP; Andrade SP Differential effects of thalidomide on angiogenesis and tumor growth in mice | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 181 | 12 | 27 | 2026 2002 AMERICAN JOURNAL OF MEDICINE 113(7):603-606 Bennett CL; Schumock GT; Desai AA; Kwaan HC; Raisch DW; Newlin R; Stadler W Thalidomide-associated deep vein thrombosis and pulmonary embolism | 3 | 6 |
| 182 | 0 | 0 | 1877 2001 BLOOD 98(11):863A-863A Bennett CL; Schumok GT; Kwaan HC; Raisch DW High incidence of thalidomide-associated deep vein thrombosis and pulmonary emboli when chemotherapy is also administered. | 0 | 3 |
| 183 | 2 | 5 | 1956 2001 JOURNAL OF CHEMICAL EDUCATION 78(6):759-761 Bennett N; Cornely K Thalidomide makes a comeback: A case discussion exercise that integrates biochemistry and organic chemistry | 0 | 2 |
| 184 | 1 | 6 | 1052 1992 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 119(4):281-283 BENSAID P; MACHET L; VAILLANT L; MACHET MC; SCOTTO B; LORETTE G ADULT LANGERHANS-CELL HISTIOCYTOSIS - REGRESSION OF PAROTID-GLAND INVOLVEMENT AFTER THALIDOMIDE TREATMENT | 13 | 18 |
| 185 | 8 | 31 | 530 1971 PEDIATRIC RESEARCH 5(5):199-& BERAN AV; STRAUSS J; SPERLING DR; NORTON AC; GARWOOD VP; YAMAZAKI J EFFECT OF THALIDOMIDE ON BRAIN OXYGENATION | 0 | 3 |
| 186 | 3 | 6 | 1207 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 33(5):837-838 BERGER TG; HOFFMAN C; THIEBERG MD PRURIGO NODULARIS AND PHOTOSENSITIVITY IN AIDS - TREATMENT WITH THALIDOMIDE | 13 | 22 |
| 187 | 6 | 15 | 291 1964 MEDICINA EXPERIMENTALIS 11(2):119-& BERGSTROM RM; BERGSTROM L; PUTKONEN P; SAINIO K EFFECTS OF THALIDOMIDE ON ELECTRICAL ACTIVITY OF BRAIN IN INTRAUTERINE GUINEA-PIG FOETUS | 1 | 3 |
| 188 | 0 | 1 | 185 1963 ACTA PHYSIOLOGICA SCANDINAVICA 59:21-& BERGSTROM RM; PUTKONEN P; BERGSTROM L EFFECT OF THALIDOMIDE ON ELECTROENCEPHALOGRAM (EEG) OF INTRAUTERINE GUINEA PIG FOETUS | 0 | 1 |
| 189 | 2 | 6 | 454 1968 BRITISH MEDICAL JOURNAL 3(5609):42-& BERKELEY JS THALIDOMIDE IN LEPROSY | 1 | 1 |
| 190 | 1 | 6 | 1059 1992 INTERNATIONAL JOURNAL OF DERMATOLOGY 31(8):599-600 BERNAL JE; DURAN MM; LONDONO F; UMANA A CELLULAR IMMUNE EFFECTS OF THALIDOMIDE IN ACTINIC PRURIGO | 8 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 191 | 7 | 12 | 2484 2003 JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 22(4):129-133 Bernardeschi P; Dentico P; Rossi S; Fiorentini G; Giustarini G; Turano E Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): Results, prognostic factors and side effects in eight patients previously treated with multiple myeloma | 0 | 0 |
| 192 | 0 | 0 | 1026 1990 MEDICINA CLINICA 94(16):638-639 BERNARDO P; ARRIZABALAGA J; IRIBARREN JA; GARDE C EFFECTIVENESS OF THALIDOMIDE IN NONSPECIFIC ESOPHAGEAL ULCERS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY SYNDROME | 3 | 4 |
| 193 | 1 | 236 | 1332 1997 COLUMBIA LAW REVIEW 97(7):2153-2176 Bernstein A Formed by thalidomide: Mass torts as a false cure for toxic exposure | 1 | 6 |
| 194 | 6 | 16 | 1810 2001 ANNALS OF ONCOLOGY 12(7):987-990 Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cineri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers | 16 | 26 |
| 195 | 1 | 1 | 1812 2001 ANNALS OF ONCOLOGY 12(9):1333-1333 Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cinieri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. (vol 12, pg 987, 2001) | 0 | 1 |
| 196 | 0 | 9 | 280 1964 COMPTES RENDUS DES SEANCES DE LA SOCIETE DE BIOLOGIE ET DE SES FILIALES 158(4):737-& BERTRAND M; FLORIO R; DELATOUR P; MAGAT A SUR LA POTENTIALISATION DES EFFETS EMBRYOTOXIQUES DU THALIDOMIDE CHEZ LA RATTE | 2 | 3 |
| 197 | 5 | 7 | 1065 1992 LANCET 339(8792):549-550 BESSIS D; GUILLOT B; MONPOINT S; DANDURAND M; GUILHOU JJ THALIDOMIDE FOR SYSTEMIC LUPUS-ERYTHEMATOSUS | 27 | 31 |
| 198 | 27 | 34 | 2033 2002 ANNALS OF PHARMACOTHERAPY 36(3):521-525 Bessmertny O; Pham T Thalidomide use in pediatric patients | 1 | 2 |
| 199 | 2 | 5 | 1534 1999 DERMATOLOGY 199(2):195-195 Bez C; Lodi G; Sardella A; Della Volpe A; Carrassi A Oral lichenoid lesions after thalidomide treatment | 5 | 5 |
| 200 | 10 | 38 | 1881 2001 BONE MARROW TRANSPLANTATION 28(12):1145-1150 Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation | 3 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 201 | 3 | 8 | 1892 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(2):484-485 Biagi JJ; Prince HM Thalidomide is effective for extramedullary relapse of multiple myeloma postallogeneic bone marrow transplantation | 1 | 1 |
| 202 | 0 | 0 | 1857 2001 BLOOD 98(11):307B-307B Bibas M; Andriani A; Ferrari A; Montanaro M; Niscola G; Recine U; Chierichini A Thalidomide treatment for relapsed/refractory multiple myeloma: A retrospective multicenter study. | 0 | 0 |
| 203 | 18 | 22 | 1138 1994 DERMATOLOGY 189(2):179-181 BIELSA I; TEIXIDO J; RIBERA M; FERRANDIZ C ERYTHRODERMA DUE TO THALIDOMIDE - REPORT OF 2 CASES | 13 | 17 |
| 204 | 0 | 0 | 2382 2003 BLOOD 102(11):554A-554A Biemond BJ; Havik SR; Meijers JCM; Levi MM; Van Oers MHJ Strong thrombogenic activity of the combined administration of thalidomide and doxorubicin in experimental thrombosis in the rabbit. | 0 | 0 |
| 205 | 0 | 1 | 787 1982 PRAXIS DER KINDERPSYCHOLOGIE UND KINDERPSYCHIATRIE 31(6):250-250 BIERMANN G THE ADOLESCENCE OF THALIDOMIDE DAMAGED CHILDREN - GERMAN - JOCHMUS,I, SCHMIDT,GM, LOHMAR,L, LOHMAR,W | 0 | 0 |
| 206 | 0 | 0 | 1470 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 358(1):R479-R479 Bignone IM; Papale RM; Seoane M; Bazerque PM Thalidomide - New trends for therapeutical use | 0 | 0 |
| 207 | 13 | 24 | 1141 1994 FOLIA BIOLOGICA 40(4):161-171 BILA V; KREN V EVIDENCE FOR TERATOGENICITY OF THALIDOMIDE USING CONGENIC AND RECOMBINANT INBRED RAT STRAINS | 0 | 10 |
| 208 | 3 | 3 | 1381 1997 NEW ENGLAND JOURNAL OF MEDICINE 337(15):1086-1087 Birnkrant D Thalidomide for aphthous ulcers in HIV infection | 1 | 2 |
| 209 | 0 | 0 | 2183 2002 EXPERIMENTAL HEMATOLOGY 30(6):60-60 Biscardi M; Gavazzi S; Balestri F; Grossi A Angiogenic growth factors (VEGF, TGF-b1, bFGF) and thalidomide effect in myelofibrosis with myeloid metaplasia | 0 | 0 |
| 210 | 6 | 18 | 2008 2001 SEMINARS IN ONCOLOGY 28(6):588-592 Blade J; Esteve J; Rosinol L; Perales M; Montoto S; Tuset M; Montserrat E Thalidomide in refractory and relapsing multiple myeloma | 11 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 211 | 5 | 12 | 1887 2001 BRITISH JOURNAL OF HAEMATOLOGY 113(2):422-424 Blade J; Perales M; Rosinol L; Tuset M; Montoto S; Esteve O; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas | 18 | 19 |
| 212 | 9 | 21 | 2439 2003 CLINICAL LYMPHOMA 3(4):247-248 Blade J; Rosinol L Thalidomide: A step forward in the treatment of malignant monoclonal gammopathies | 0 | 0 |
| 213 | 5 | 7 | 447 1968 AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 102(8):1179-& BLAKE DA; FLEISCHE.CA; WYNN RL; GUSDON JP; COHEN C THALIDOMIDE SOLUTION | 0 | 0 |
| 214 | 0 | 0 | 788 1982 TERATOLOGY 25(2):A28-A29 BLAKE DA; GORDON GB; SPIELBERG SP THE ROLE OF METABOLIC-ACTIVATION IN THALIDOMIDE TERATOGENESIS | 0 | 0 |
| 215 | 2 | 11 | 722 1980 CHEMISCHE BERICHTE-RECUEIL 113(6):2318-2322 BLASCHKE G; KRAFT HP; MARKGRAF H CHROMATOGRAPHIC RESOLUTIONS OF RACEMATES .10. OPTICAL RESOLUTION OF THALIDOMIDE AND OTHER GLUTARIMIDE DERIVATIVES | 7 | 31 |
| 216 | 9 | 18 | 2186 2002 FARMACO 57(7):551-554 Blaschke G; Meyring M; Muhlenbrock C; Chankvetadze B Recent results of biotransformation of drugs: investigation of the in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 0 | 2 |
| 217 | 13 | 23 | 106 1962 JOURNAL OF PEDIATRICS 61(1):153-& BLATTNER RJ DRUGS IN PREGNANCY - THALIDOMIDE | 3 | 3 |
| 218 | 4 | 4 | 108 1962 JOURNAL OF PEDIATRICS 61(2):318-& BLATTNER RJ THALIDOMIDE STUDIES IN EXPERIMENTAL ANIMALS | 3 | 5 |
| 219 | 0 | 8 | 414 1967 AGRI HORTIQUE GENETICA 25(3-4):99-& BLIXT S STUDIES OF INDUCED MUTATION IN PEAS .19. TREATMENT WITH HYDROXYLAMINE FLUORODEOXYURIDIN DEOXYURIDIN AND THALIDOMIDE | 0 | 2 |
| 220 | 2 | 2 | 254 1963 POULTRY SCIENCE 42(6):1479-& BLOW WL; COOK FW; KARE MR EFFECTS OF THALIDOMIDE ON REPRODUCTION IN CHICKENS | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 221 | 2 | 3 | 1111 1993 PRESSE MEDICALE 22(26):1233-1233 BODOKH I; LACOUR JP; RAINERO C; CASTANET J; MICHIELS JF; ORTONNE JP EFFECTIVENESS OF THALIDOMIDE AGAINST ESOPHAGEAL ULCERATION IN HIV-INFECTION | 3 | 3 |
| 222 | 3 | 5 | 389 1966 LANCET 1(7428):92-& BOHM R; NITSCH K ANOTHER CHANCE FOR THALIDOMIDE | 1 | 1 |
| 223 | 13 | 15 | 2203 2002 HAUTARZT 53(11):744-748 Bohmeyer J; Achenbach A; Westenberger M; Stadler R Thalidomide therapy of cutaneous lupus erythematosus | 1 | 1 |
| 224 | 4 | 29 | 1379 1997 NEUROSCIENCE LETTERS 234(2-3):123-126 Boireau A; Bordier F; Dubedat P; Peny C; Imperato A Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice | 0 | 9 |
| 225 | 0 | 7 | 247 1963 NATURE 198(488):1068-& BONEY AD ABNORMAL GROWTH OF SPORELINGS OF A MARINE RED ALGA INDUCED BY THALIDOMIDE | 3 | 10 |
| 226 | 0 | 0 | 2508 2003 LANCET ONCOLOGY 4(2):70-70 Bonn D Thalidomide: no benefit in myelofibrosis with myeloid metaplasia | 0 | 0 |
| 227 | 8 | 9 | 1257 1996 DERMATOLOGY 193(4):321-323 Bonnetblanc JM; Royer C; Bedane C Thalidomide and recurrent aphthous stomatitis: A follow-up study | 5 | 10 |
| 228 | 3 | 7 | 298 1964 POULTRY SCIENCE 43(2):506-& BOONE MA; BARNETT BD; HAMMOND M EFFECT OF THALIDOMIDE ON CHICKENS + EMBRYOS | 1 | 3 |
| 229 | 0 | 0 | 252 1963 POULTRY SCIENCE 42(5):1257-& BOONE MA; HAMMOND M; BARNETT BD EFFECT OF THALIDOMIDE ON DOMESTIC FOWL | 2 | 0 |
| 230 | 10 | 19 | 398 1966 LANCET 1(7449):1240-& BORE PJ; SCOTHORN.RJ EFFECT OF THALIDOMIDE ON SURVIVAL OF SKIN HOMOGRAFTS IN RABBITS | 16 | 18 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 231 | 0 | 0 | 1916 2001 DIABETES 50:A473-A473 Bosco A; Lerario AC; Santos RF; Ferreira A; Ursich MJ; Silva ME; Rocha DM; Wajchenberg BL Study of Thalidomide and Rosiglitazone effects on the prevention of diabetic retinopathy of Streptozotocin diabetic rats | 0 | 0 |
| 232 | 6 | 42 | 2448 2003 DIABETOLOGIA 46(12):1669-1675 Bosco AA; Lerario AC; Santos RF; Wajchenberg BL Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats | 1 | 1 |
| 233 | 1 | 1 | 2616 2004 DIABETOLOGIA 47(5):963-963 Bosco AA; Lerario AC; Santos RF; Wajchenberg BL Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats (vol 46, pg 1669, 2003) | 0 | 0 |
| 234 | 0 | 0 | 2474 2003 JOURNAL OF BONE AND MINERAL RESEARCH 18:S310-S310 Bose N; Bergemann H; Westendorf JJ; Rajkumar SV; Masellis AM Expression of alternatively spliced Runx2 in multiple myeloma patients and a shift in expression in response to thalidomide treatment. | 0 | 0 |
| 235 | 0 | 0 | 928 1986 MEDICINA-BUENOS AIRES 46(5):528-528 BOTTASSO OA; MORINI JC; REGGIARDO Z ANTIBODIES AGAINST BCG GLYCOLIPIDS IN LEPROMATOUS PATIENTS TREATED WITH THALIDOMIDE OR LEPROUS KNOTTED ERYTHEMA | 0 | 0 |
| 236 | 17 | 34 | 2175 2002 DRUG NEWS & PERSPECTIVES 15(9):604-611 Botting J The history of thalidomide | 0 | 1 |
| 237 | 11 | 14 | 1168 1995 ANNALS OF CLINICAL BIOCHEMISTRY 32:79-83 BOUGHTON BJ; SHEEHAN TMT; WOOD J; OBRIEN D; BUTLER M; SIMPSON A; HALE KA HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY OF PLASMA THALIDOMIDE - STABILIZATION OF SPECIMENS AND DETERMINATION OF A TENTATIVE THERAPEUTIC RANGE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 17 | 17 |
| 238 | 22 | 32 | 2291 2002 THERAPIE 57(6):524-529 Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ Role of thalidomide with or without dexamethasone for refractory multiple myeloma | 0 | 0 |
| 239 | 0 | 0 | 976 1988 LEPROSY REVIEW 59(2):184-185 BOURDILLON C THALIDOMIDE IN ERYTHEMA-NODOSUM LEPROSUM (ENL) | 0 | 0 |
| 240 | 47 | 67 | 1920 2001 DRUGS 61(6):777-787 Bousvaros A; Mueller B Thalidomide in gastrointestinal disorders | 4 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 241 | 8 | 10 | 1054 1992 ARCHIVES OF INTERNAL MEDICINE 152(5):1089-1090 BOUZA E; MUNOZ P; DIAZ MD; VICENTE T THALIDOMIDE IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME | 3 | 6 |
| 242 | 0 | 0 | 1353 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 14(4):76-76 Bower M; Howard M; Gracie F; Phillips R; Fife K A phase II study of thalidomide for Kaposi's sarcoma: Activity and correlation with KSHV DNA load | 1 | 2 |
| 243 | 2 | 2 | 808 1983 BRITISH MEDICAL JOURNAL 287(6395):799-800 BOWERS PW; POWELL RJ EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION | 19 | 25 |
| 244 | 0 | 0 | 811 1983 BRITISH MEDICAL JOURNAL 287(6404):1550-1550 BOWERS PW; POWELL RJ EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION - REPLY | 1 | 1 |
| 245 | 7 | 10 | 2246 2002 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(6):967-968 Boyd AS; King LE; Boyd AS Thalidomide-induced remission of lichen planopilaris | 0 | 0 |
| 246 | 11 | 24 | 279 1964 CANADIAN JOURNAL OF BIOCHEMISTRY AND PHYSIOLOGY 42(1):35-& BOYLEN JB; HORNE HH; JOHNSON WJ TERATOGENIC EFFECTS OF THALIDOMIDE + ITS METABOLITES ON DEVELOPING CHICK EMBRYO | 12 | 17 |
| 247 | 2 | 2 | 230 1963 LANCET 1(728):552-& BOYLEN JB; JOHNSON WJ; HORNE HH TERATOGENIC EFFECTS OF THALIDOMIDE AND RELATED SUBSTANCES | 20 | 33 |
| 248 | 0 | 0 | 1752 2000 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 35(2):172A-173A Bozkurt B; Chee A; Lee-Jackson D; Deswal A; Zeldis JB; Mann DL Results of an open label dose response study of thalidomide in patients with advanced heart failure and elevated levels of TNF | 0 | 2 |
| 249 | 0 | 0 | 862 1984 TERATOLOGY 29(2):A19-A20 BRAUN AG; COLLINS M; HARDING F; WEINREB S FACTORS INFLUENCING THE ACTIVATION OF THALIDOMIDE TO A PRODUCT INHIBITING ATTACHMENT OF TUMOR-CELLS TO LECTIN COATED SURFACES | 0 | 1 |
| 250 | 0 | 0 | 732 1980 TERATOLOGY 21(2):A29-A29 BRAUN AG; DAILEY JP THALIDOMIDE METABOLITE INHIBITS TUMOR-CELL ATTACHMENT TO LECTIN COATED SURFACES | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 251 | 5 | 20 | 746 1981 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 98(4):1029-1034 BRAUN AG; DAILEY JP THALIDOMIDE METABOLITE INHIBITS TUMOR-CELL ATTACHMENT TO CONCANAVALIN A COATED SURFACES | 6 | 16 |
| 252 | 3 | 15 | 934 1986 TOXICOLOGY AND APPLIED PHARMACOLOGY 82(1):175-179 BRAUN AG; HARDING FA; WEINREB SL TERATOGEN METABOLISM - THALIDOMIDE ACTIVATION IS MEDIATED BY CYTOCHROME-P-450 | 27 | 34 |
| 253 | 0 | 0 | 834 1983 TERATOLOGY 27(2):A33-A33 BRAUN AG; WEINREB SL METABOLITES OF THALIDOMIDE ANALOGS INHIBIT ATTACHMENT OF CELLS TO CONCANAVALIN A COATED SURFACES | 0 | 2 |
| 254 | 9 | 24 | 845 1984 BIOCHEMICAL PHARMACOLOGY 33(9):1471-1477 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - ACTIVATION OF THALIDOMIDE AND THALIDOMIDE ANALOGS TO PRODUCTS THAT INHIBIT THE ATTACHMENT OF CELLS TO CONCANAVALIN A COATED PLASTIC SURFACES | 15 | 24 |
| 255 | 6 | 12 | 907 1985 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 5(3):149-158 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - SPONTANEOUS DECAY PRODUCTS OF THALIDOMIDE AND THALIDOMIDE ANALOGS ARE NOT BIOACTIVATED BY LIVER-MICROSOMES | 11 | 15 |
| 256 | 0 | 0 | 2132 2002 BRITISH JOURNAL OF CANCER 86:S42-S42 Braybrooke JP; Madhusudan S; Blann A; Wilner S; Flanagan E; Jenkins A; Echeta C; Perren T; Ganesan TS Randomised phase two study of carboplatin versus carboplatin and thalidomide in patients with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. | 0 | 0 |
| 257 | 1 | 4 | 1820 2001 ARTHRITIS AND RHEUMATISM 44(10):2457-2458 Breban M; Dougados M The efficacy of thalidomide in severe refractory seronegative spondylarthropathy: Reply | 2 | 5 |
| 258 | 3 | 8 | 1490 1999 ARTHRITIS AND RHEUMATISM 42(3):580-581 Breban M; Gombert B; Amor B; Dougados M Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis | 16 | 53 |
| 259 | 0 | 0 | 2357 2003 BLOOD 102(11):381B-381B Breitkreutz I; Cremer FW; Benner A; Moehler T; Fruehauf S; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide administration. | 0 | 0 |
| 260 | 0 | 0 | 2100 2002 BLOOD 100(11):390B-390B Breitkreutz I; Cremer FW; Benner A; Raab MS; Moehler T; Egerer G; Christensen O; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide (Thai) administration. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 261 | 1 | 3 | 674 1978 LANCET 1(8068):826-826 BREMNER DN; MOONEY G AGENESIS OF APPENDIX - FURTHER THALIDOMIDE ANOMALY | 0 | 5 |
| 262 | 7 | 25 | 2627 2004 HAEMATOLOGICA 89(5):552-556 Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A Low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma | 0 | 0 |
| 263 | 0 | 0 | 1448 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):693-693 Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse epidermal cell apoptosis by a TNF-alpha dependent pathway. | 0 | 0 |
| 264 | 12 | 37 | 285 1964 JOURNAL OF PEDIATRICS 64(5):762-& BRENT RL DRUG TESTING IN ANIMALS FOR TERATOGENIC EFFECTS - THALIDOMIDE IN PREGNANT RAT | 5 | 39 |
| 265 | 22 | 219 | 984 1988 TERATOLOGY 38(3):241-251 BRENT RL; HOLMES LB CLINICAL AND BASIC SCIENCE LESSONS FROM THE THALIDOMIDE TRAGEDY - WHAT HAVE WE LEARNED ABOUT THE CAUSES OF LIMB DEFECTS | 6 | 36 |
| 266 | 8 | 10 | 2678 2004 NEUROLOGY 62(12):2288-2290 Briani C; Zara G; Rondinone R; Della Libera S; Ermani M; Ruggero S; Ghirardello A; Zampieri S; Doria A Thalidomide neurotoxicity - Prospective study in patients with lupus erythematosus | 1 | 1 |
| 267 | 9 | 16 | 1996 2001 PEDIATRIC DERMATOLOGY 18(2):143-145 Brik R; Shamali H; Bergman R Successful thalidomide treatment of severe infantile Behcet disease | 1 | 1 |
| 268 | 0 | 0 | 2071 2002 BLOOD 100(11):178A-178A Brinker B; Waller EK; Langston AA; Redei I; Smith KJ; Bucur SZ; Winton E; Lyles R; Heffner LT; Lonial S Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma. | 0 | 0 |
| 269 | 0 | 16 | 1008 1990 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 115(25):977-979 BROCHELER J; HALFMANN R ANTERIOR SACRAL MENINGOCELE ASSOCIATED WITH THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 270 | 8 | 11 | 2551 2003 PRESSE MEDICALE 32(40):1894-1898 Brocvielle H; Muret P; Plenat E; Kantelip JP; Humbert P Management of a patient receiving thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 271 | 4 | 22 | 450 1968 ARZNEIMITTEL-FORSCHUNG 18(6):661-& BRODE E EXPERIMENTAL STUDIES ON CYCLIC IMIDES .I. INFLUENCE OF THALIDOMIDE ON PITUITARY-ADRENAL AXIS | 1 | 2 |
| 272 | 6 | 18 | 451 1968 ARZNEIMITTEL-FORSCHUNG 18(10):1313-& BRODE E EXPERIMENTAL STUDIES ON CYCLIC IMIDES .4. CLEAVING OF PHTHALIMIDE RING IN THALIDOMIDE BY AMINES | 6 | 10 |
| 273 | 1 | 2 | 895 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(3):509-509 BRODTHAGEN H SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT | 1 | 1 |
| 274 | 1 | 9 | 637 1977 ACTA PAEDIATRICA SCANDINAVICA 66(6):673-675 BROOK CGD; JARVIS SN; NEWMAN CGH LINEAR GROWTH OF CHILDREN WITH LIMB DEFORMITIES FOLLOWING EXPOSURE TO THALIDOMIDE INUTERO | 3 | 3 |
| 275 | 0 | 0 | 1374 1997 NATURE BIOTECHNOLOGY 15(11):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 1 |
| 276 | 0 | 0 | 1375 1997 NATURE BIOTECHNOLOGY 15(12):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 0 |
| 277 | 0 | 0 | 31 1961 BRITISH MEDICAL JOURNAL 2(526):1359-& BROWN JA NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 2 | 2 |
| 278 | 0 | 2 | 1385 1997 SCIENTIST 11(3):1-& Brown KS New uses for thalidomide yielding valuable lessons | 1 | 4 |
| 279 | 1 | 1 | 1386 1997 SCIENTIST 11(3):8-8 Brown KS Researchers explore thalidomide's therapeutic potential | 0 | 0 |
| 280 | 2 | 7 | 1024 1990 MEDICAL JOURNAL OF AUSTRALIA 152(3):148-149 BROWN MA; FARRELL C; NEWTON P; CHILD RP THALIDOMIDE, PREGNANCY AND RENAL-FAILURE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 281 | 0 | 0 | 1176 1995 BLOOD 86(10):1577-1577 Browne PV; Wagner J; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NKC; Enright H Response to thalidomide therapy in patients with refractory chronic graft-versus-host disease. | 0 | 0 |
| 282 | 9 | 19 | 1680 2000 BONE MARROW TRANSPLANTATION 26(8):865-869 Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NKC; Wagner J; Enright H Response to thalidomide therapy in refractory chronic graft-versus-host disease | 11 | 17 |
| 283 | 4 | 24 | 1398 1998 ANTICANCER RESEARCH 18(6A):4409-4413 Browne WL; Wilson WR; Baguley BC; Ching LM Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid | 5 | 13 |
| 284 | 6 | 12 | 1486 1999 ANNALS OF ONCOLOGY 10(7):857-859 Bruera E; Neumann CM; Pituskin E; Calder K; Ball G; Hanson J Thalidomide in patients with cachexia due to terminal cancer: Preliminary report | 14 | 30 |
| 285 | 7 | 27 | 1005 1990 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 40-1(1):32-36 BUCH HP; OMLOR G; KNABE J STEREOSELECTIVE DIFFERENCES OF THE CNS-DEPRESSANT ACTIVITY IN A HOMOLOGOUS SERIES OF 3-ALKYL-THALIDOMIDE ANALOGS | 0 | 5 |
| 286 | 3 | 24 | 199 1963 BRITISH MEDICAL JOURNAL (536):973-& BUCKLE RM BLOOD PYRUVIC ACID IN THALIDOMIDE NEUROPATHY | 0 | 0 |
| 287 | 0 | 0 | 418 1967 ARZNEIMITTEL-FORSCHUNG 17(5):646-& BUELENS I TREATMENT WITH THALIDOMIDE OF AN ASTROCYTOMA OF SECOND DEGREE (N-PHTHALYGLUTAMIC ACID IMIDE) | 2 | 3 |
| 288 | 0 | 1 | 2424 2003 BRITISH MEDICAL JOURNAL 327(7418):767-767 Burgermeister J Head of German medicines body likens HRT to thalidomide | 0 | 0 |
| 289 | 2 | 13 | 750 1981 EUROPEAN JOURNAL OF PEDIATRICS 136(3):229-230 BURGIO GR THE THALIDOMIDE DISASTER BRIEFLY REVISITED | 3 | 4 |
| 290 | 0 | 0 | 193 1963 BIOLOGICAL BULLETIN 125(2):373-& BURKE JA; SPEAR JF SOME MORPHOLOGICAL AND PHYSIOLOGICAL EFFECTS OF THALIDOMIDE ON EMBRYOS OF FUNDULUS HETEROCLITUS | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 291 | 0 | 0 | 2269 2002 NEUROBIOLOGY OF AGING 23(1):S93-S93 Burke W; Bohac D; Cotter R; Zheng JL; Potter J; Gendelman H A 26 week double blind, placebo-controlled study of the efficacy of thalidomide in the treatment of Alzheimer's disease | 0 | 0 |
| 292 | 0 | 0 | 14 1961 BRITISH MEDICAL JOURNAL 1(521):130-& BURLEY D IS THALIDOMIDE TO BLAME | 17 | 19 |
| 293 | 0 | 0 | 13 1961 BRITISH MEDICAL JOURNAL 1(521):130-& BURLEY DM IS THALIDOMIDE TO BLAME | 0 | 0 |
| 294 | 1 | 1 | 113 1962 LANCET 1(7220):100-& BURLEY DM THALIDOMIDE AND CONGENITAL ABNORMALITIES | 8 | 10 |
| 295 | 0 | 0 | 116 1962 LANCET 1(7223):271-& BURLEY DM THALIDOMIDE AND CONGENITAL ABNORMALITIES | 13 | 19 |
| 296 | 6 | 23 | 1212 1995 MICROBIAL PATHOGENESIS 19(4):245-255 BURROUGHS MH; TSENOVABERKOVA L; SOKOL K; OSSIG J; TUOMANEN E; KAPLAN G EFFECT OF THALIDOMIDE ON THE INFLAMMATORY RESPONSE IN CEREBROSPINAL-FLUID IN EXPERIMENTAL BACTERIAL-MENINGITIS | 10 | 19 |
| 297 | 0 | 0 | 82 1962 BRITISH MEDICAL JOURNAL (5317):1462-& BURROWS HJ; RITCHIE T; WILSON K; SHARRARD WJ; CHAMBERLAIN R; SWETNAM; WIGGLESWORTH R; MCKENZIE DS; GILLIS L; JOLLY DW; WINNER A MANAGEMENT OF THALIDOMIDE DEFORMITIES | 0 | 0 |
| 298 | 3 | 4 | 1092 1993 BRITISH MEDICAL JOURNAL 307(6909):939-940 BURROWS NP DIAGNOSIS AND MANAGEMENT OF SYSTEMIC LUPUS-ERYTHEMATOSUS - THALIDOMIDE MODIFIES DISEASE | 1 | 1 |
| 299 | 2 | 34 | 1036 1991 BRITISH JOURNAL OF DERMATOLOGY 125(1):62-67 BURROWS NP; WALPORT MJ; HAMMOND AH; DAVEY N; JONES RR LUPUS-ERYTHEMATOSUS PROFUNDUS WITH PARTIAL C4-DEFICIENCY RESPONDING TO THALIDOMIDE | 12 | 23 |
| 300 | 0 | 0 | 645 1977 CANADIAN VETERINARY JOURNAL-REVUE VETERINAIRE CANADIENNE 18(5):135-136 BUTLER H EFFECT OF THALIDOMIDE ON NONHUMAN-PRIMATES | 0 | 0 |
Page 1: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22